

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

ANTIGENICS INC /DE/  
Form 8-K  
July 10, 2006

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K  
-----

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

July 6, 2006  
Date of Report (Date of earliest event reported)

-----  
ANTIGENICS INC.  
(Exact name of registrant as specified in its charter)

-----  
DELAWARE                                000-29089                                06-1562417  
(State or other jurisdiction                (Commission                                (IRS Employer  
of incorporation)                                File Number)                                Identification No.)

630 Fifth Avenue, Suite 2100  
New York, NY 10111                                10111  
(Address of principal executive offices)                                (Zip Code)

212-994-8200  
(Registrant's telephone number, including area code)

-----  
Check the appropriate box below if the Form 8-K filing is intended to  
simultaneously satisfy the filing obligation of the registrant under any of the  
following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act  
(17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act  
(17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange  
Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange  
Act (17 CFR 240.13e-4(c))

Item 1.01                    Entry into a Material Definitive Agreement

On July 6, 2006, Antigenics Inc. entered into expanded license  
and supply agreements for the use of QS-21 Stimulon(R) adjuvant with  
GlaxoSmithKline Biologicals, a vaccine division of GlaxoSmithKline (GSK). Under  
the terms of the agreements, GSK will purchase a percentage of its QS-21 supply

## Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

requirements from Antigenics through 2014. Antigenics will also transfer manufacturing technologies to GSK under the supply agreement. GSK will make payments contingent upon successful milestone achievements, and will pay royalties to Antigenics on net sales for a period of at least 10 years after first commercial sale under the supply agreement.

### Item 7.01 Regulation FD Disclosure

On July 10, 2006, Antigenics Inc. issued a press release announcing the execution of the agreements described in Item 1.01 above. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

### Item 9.01 Financial Statements and Exhibits

#### (d) Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated July 10, 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTIGENICS INC.

Date: July 10, 2006

By: /s/ Garo H. Armen, Ph.D.  
-----  
Garo H. Armen, Ph.D.  
Chairman and Chief Executive Officer

#### EXHIBIT INDEX

Exhibit No. -----	Description of Exhibit -----
99.1	Press Release dated July 10, 2006